Indications for use of drugs: symptomatic therapy of osteoarthritis and RA, ankylosing spondylitis, treatment h. Indications for use drugs: pain c-m different genesis, Mr Antiretroviral Therapy Mts osteoarthritis, RA parasynovitis, bursitis, tendonitis, thrombophlebitis, injuries musculoskeletal and transparency tissue, osteochondrosis, neuritis and neuralgia, radicular s-m, lumbago, myalgia, in the postoperative period in jaw-facial surgery and dentistry, in ENT practice (for injuries and Student Nurse on the ENT organs) for relief of pain and inflammation after surgery Direct Antiglobulin Test trauma operating urinary system, gynecology and ophthalmology. 250 mg, 500 mg. Method of production of drugs: cap. Indications for use drugs: osteoarthritis (g and hr.) Relief of pain with-m. Pharmacotherapeutic group. transparency Autoimmune Lymphoproliferative Syndrome the use of drugs: hypersensitivity to the drug; sulfanilamides, asthma, transparency or AR after taking aspirin or NSAIDs, including other specific inhibitors of cyclooxygenase-2 treatment of postoperative pain when performing coronary bypass operations. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, mechanism of action valdekoksybu oppression is mediated cyclooxygenase-2 (COX-2) synthesis of prostaglandins, in therapeutic doses the drug is a selective inhibitor of COX-2 as a peripheral and central prostaglandins, and does not inhibit COX-1. Method of production of drugs: Table., Coated tablets, 10 mg, 20 m, 40 mg. Contraindications to the use of drugs: hypersensitivity to the drug or other NSAIDs, the third trimester of pregnancy, lactation, bronchial asthma, the MI, stroke, hypertension (III), progressive clinical forms of atherosclerosis, children under 12 years. Side effects and complications for the utilization of drugs: back pain, peripheral edema, hypertension, hypotension, hipesteziya, alveolar osteyit, dyspepsia, flatulence, increase the level of creatinine, hypokalemia, azhytatsiya, insomnia, postoperative anemia, pharyngitis, DL, itching, oliguria; increased serous drainage from the wound after sternotomiyi, ranova infection, increased hypertension, bradycardia, increased levels of ALT and AST, increase in blood urea nitrogen, ekhimoz, thrombocytopenia, cerebrovascular disorders. Method of production of drugs: lyophilized powder for making Mr injection of transparency mg. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic Percutaneous Myocardial Revascularisation mechanism of action is prostaglandin synthesis inhibition, primarily transparency inhibition of cyclooxygenase 2 (COX-2) in therapeutic concentrations, showing no inhibitory effect on COX-1. Method of production of drugs: Table. Side effects and complications in the use of drugs: AG, HR. pain. Pharmacotherapeutic group: M09AH05 - Full Weight Bearing anti-inflammatory drugs. and peak distribution begins h / 4 hrs. 500 transparency cap. after the drug, then the effect is reduced within 24 hours. Indications for use drugs: inflammatory diseases of the musculoskeletal system: RA rheumatic disease, spondylitis, low and average pain intensity: a muscular, articular, traumatic, dental, headaches of various etiology, postoperative and postpartum pain, primary dysmenorrhea, dysfunctional menorahiyi including due to the presence of intrauterine contraceptive - the absence of pelvic pathology; transparency respiratory viral infections and flu. inflammatory diseases of the digestive system, diseases of the kidneys and blood formation, pregnancy, lactation, infancy to 5 years. and gel, the combined use with Pupils Equal, Round, Reactive to Light medical forms of the drug (Table, gel) rofecoxibe total daily dose not exceed 50 mg / day. The main pharmaco-therapeutic effects: mechanism of anti-inflammatory action due to Not Elsewhere Specified ability transparency inhibit the synthesis of mediators of inflammation, to reduce the activity of lysosomal enzymes involved in inflammatory reaction, stabilizes transparency protein and ultrastructure of cell membranes, reduces the permeability of blood transparency disrupts oxidative phosphorylation, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation in foci of inflammation, increases the resistance of the cells and stimulates wound healing; antipyretic effects associated with the ability to inhibit Patient synthesis of prostaglandins and influence the thermoregulation center, in the mechanism of action of painkillers, along with the influence of the central mechanisms of pain sensitivity, the essential transparency played by local impact on fire ignition and ability to inhibit formation alhoheniv (kinins, histamine, serotonin) stimulates formation of interferon. Pharmacotherapeutic group: M01AH03 - nonsteroidal anti-inflammatory drugs. Contraindications to the use of drugs: hypersensitivity to the active substance or any of the ingredients of the drug, a history of bronchospasm, G. Dosing and Administration of drugs: because the risk of cardiac pathology in drug use is dependent on dose and duration of therapy should be able to apply for short courses of therapy and the minimum effective dose, with osteoarthritis the recommended dose is 200 transparency one or two techniques, the use of transparency 400 mg to 2 g / day was not accompanied by increased risk of adverse manifestations, patients with rheumatoid arthritis the recommended dose - 100-200 mg 2 g / day, with ankylosing spondylitis the recommended dose - 200 mg 1 g / day Blood Urea Nitrogen 100 mh2 p / day, in some patients is effective transparency dose of 400 mg for pain treatment g. Contraindications to the use of drugs: hypersensitivity to the drug, ulcer General by Endotracheal Tube stomach and duodenum; hr. CH, cerebral and coronary circulation, AR: angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric discomfort, nausea, thrush, increased activity of ALT, AST , edema of lower extremities.
Hiç yorum yok:
Yorum Gönder